Sanofi received approval from the FDA for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of 2Q15.   The approval was based on results from the EDITION clinical trial program evaluating the efficacy and safety of Toujeo in more than 3,500 adults with type 1 and type 2 diabetes. All studies in the program successfully met t...